Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Cancer Chemother Pharmacol. 2014 Nov 15;75(1):143–152. doi: 10.1007/s00280-014-2623-5

Fig. 2.

Fig. 2

Representative substance P (SP) immunolabeling in the substantia gelatinosa of the musk shrew spinal cord, the terminal location of spinal afferent fibers [46]. The images show the effects of removing the primary antibody from the immunohistochemistry protocol compared to including a concentration of 1:5,000. Lower image is a higher magnification of the SP labeling in the upper right panel.